Achondroplasia Treatment Market

Achondroplasia Treatment Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : 200

To learn more about this report, request a free sample copy

Achondroplasia Treatment Market Overview

An overview of conceptual frameworks, analytical approaches of the Achondroplasia Treatment market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The Achondroplasia Treatment market is expected to grow at a significant rate in the near future.

MMC Overview

The non-identical approach of Reports and Insights stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.

Achondroplasia Treatment Market Dynamics

The rising prevalence of achondroplastic dwarfism with no cure or prevention remedies is expected to drive the growth of the achondroplasia treatment market around the globe. For instance, according to the National Organization of Rare Disorders, 2018, achondroplasia is the most commonly occurring abnormality of bone growth, occurring in approximately 1 in 20,000-30,000 live births. Further, a short-term treatment of the growth hormone is an effective way to treat achondroplasia which is beneficial for the growth of the bones.

Further, leg-lengthening surgeries are also done in special cases to prevent loss of function. Moreover, there is a large number of symptoms that are caused due to achondroplasia which can be treated by using drugs and hence increasing the global achondroplasia treatment market.

Furthermore, increasing government funding, for such abnormalities also drives the revenue growth of the global achondroplasia treatment market in the coming years. The rising development of drugs combined with the growing awareness of this abnormality in developing countries is expected to create lucrative growth opportunities for the growth of the target market globally in the coming years.

Additionally, short-duration effectiveness of available therapy creates an opportunity for the key players for the development of new treatment therapies. However, a lack of awareness regarding achondroplastic dwarfism is expected to act as a barrier in the growth of the global achondroplasia treatment market.

Achondroplasia Treatment Market Segmentation

The Achondroplasia Treatment market is segmented on the basis of

By Product Type:

By Drugs

RBM-007

TA-46

B-701

Others

By Therapy

Growth Hormone Therapy

Surgery

Supportive Therapy

By End User:

Hospitals

Clinics

Others

By Region:

North America

Europe

Asia Pacific

Latin America

Middle East

Africa

Achondroplasia Treatment Market Pipeline Drugs and Therapies Overview

Investigation of a C-type natriuretic peptide (CNP) analog is one of the most advanced therapeutic options for the treatment of achondroplasia, which acts a counterbalance to the effect of FGFR­3. It was assumed that increasing CNP activity could respond to the excess negative signal of FGFR3 mutations which appeared to be true. An analog was developed by BioMarin Pharmaceuticals with greater stability, and animal experiments have been completed using this peptide, called BMN-111 or Vosoritide. Human trials for this drug have begun and are in phase 2 trials in young children and active recruitment for phase 3 trials.

Furthermore, Meclizine, a drug that improves the growth of the long bone in mouse through inhibition of the downstream effectors of FGFR3 have been sent for the phase 1 clinical trial. Other suggested therapies include the use of mesenchymal stem cells for the source of native CNP. Also, stain treatment of the rescued stem cells would help to treat achondroplasia.

Moreover, some suggested experimental protocols for the treatment of achondroplasia is inhibition of chaperone proteins of FGFR3, which help in the degradation of FGFR3   and, in turn, decrease its signaling. Use of decoy, soluble FGFR3 which is used to decrease binding of FGFs and consequently decrease the signaling of the protein. This therapy has entered early clinical trials. Other experimental protocols include direct blocking of the FGFR3 binding domain and reducing the activity of FGFR3 using a tyrosine kinase inhibitor.

Achondroplasia Treatment Market Drug Pipeline Image

Source: NCBI, 2019

Achondroplasia Treatment Market Competitive Landscape

Some of the key participating players in the achondroplasia treatment market are

Ascendis Pharma A/S

BioMarin Pharmaceutical Inc.

Ribomic Inc.

BridgeBio Pharma Inc.

QED Therapeutics

BioMarin Pharmaceutical Inc.

Pfizer Inc.

Achondroplasia Treatment Market Regional Segmentation

On the basis of region, the achondroplasia treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth include (but not restricted to):

•    New product designs and launches

•    Current product compliance

•    Reimbursement

•    Concerns for use of Achondroplasia Drugs and Therapies

•    Advantage of Achondroplasia Drugs and Therapies over other modalities

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at the regional level and in major countries globally for providing regional insights into the product segment in the report. This helps our clients to make an informed decision.

A mix of top-down and bottom-up approach is followed to arrive at and validate our market value estimations. For a product segment wherein one/two manufacturer(s) dominates the market, its product sales, previous growth rates, and market expansion plans are considered to generate market share in the global market.


To learn more about this report, request a free sample copy


1.    Global Achondroplasia Treatment Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Achondroplasia Treatment Market Overview

2.1.    Introduction

2.1.1.    Introduction

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Achondroplasia Treatment Market Snapshot

2.4.    Global Achondroplasia Treatment Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Achondroplasia Treatment Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Achondroplasia Treatment Market, By Product Type

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Product Type

3.1.2.    BPS Analysis, By Product Type

3.2.    Market Revenue (US$Mn) Forecast, By Product Type

3.2.1.    RBM-007

3.2.2.    TA-46

3.2.3.    B-701

3.2.4.    Others

3.3.    Global Achondroplasia Treatment Market Attractiveness Index, By Product Type

4.    Global Achondroplasia Treatment Market, By End User

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By End User

4.1.2.    BPS Analysis, By End User

4.2.    Market Revenue (US$Mn) Forecast, By End User

4.2.1.    Hospitals

4.2.2.    Clinics

4.2.3.    Others

5.    Global Achondroplasia Treatment Market, By Region

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Region

5.1.2.    BPS Analysis, By Region

5.2.    Market Revenue (US$Mn) Forecast, By Region

5.2.1.    North America

5.2.2.    Latin America

5.2.3.    Europe

5.2.4.    Asia Pacific

5.2.5.    Middle East

5.2.6.    Africa

5.3.    Global Achondroplasia Treatment Market Attractiveness Index, By Region

6.    North America Achondroplasia Treatment Market Analysis and Forecast, 2020–2028

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Country

6.1.2.    BPS Analysis, By Country

6.2.    Market Revenue (US$Mn) Forecast, By Country

6.2.1.    U.S. Achondroplasia Treatment Market

6.2.2.    Canada Achondroplasia Treatment Market

6.3.    North America Achondroplasia Treatment Market, By Product Type

6.3.1.    RBM-007

6.3.2.    TA-46

6.3.3.    B-701

6.3.4.    Others

6.4.    North America Achondroplasia Treatment Market, By End User

6.4.1.    Hospitals

6.4.2.    Clinics

6.4.3.    Others

6.5.    North America Achondroplasia Treatment Market Attractiveness Index

6.5.1.    By Country

6.5.2.    By End User

6.5.3.    By Product Type

7.    Latin America Achondroplasia Treatment Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market (US$Mn) Forecast, By Country

7.2.1.    Brazil Achondroplasia Treatment Market

7.2.2.    Mexico Achondroplasia Treatment Market

7.2.3.    Argentina Achondroplasia Treatment Market

7.2.4.    Rest of Latin America Achondroplasia Treatment Market

7.3.    Latin America Achondroplasia Treatment Market, By Product Type

7.3.1.    RBM-007

7.3.2.    TA-46

7.3.3.    B-701

7.3.4.    Others

7.4.    Latin America Achondroplasia Treatment Market, By End User

7.4.1.    Hospitals

7.4.2.    Clinics

7.4.3.    Others

7.5.    Latin America Achondroplasia Treatment Market Attractiveness Index

7.5.1.    By Country

7.5.2.    By End User

7.5.3.    By Product Type

8.    Europe Achondroplasia Treatment Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    U.K. Achondroplasia Treatment Market

8.2.2.    Germany Achondroplasia Treatment Market

8.2.3.    Italy Achondroplasia Treatment Market

8.2.4.    France Achondroplasia Treatment Market

8.2.5.    Spain Achondroplasia Treatment Market

8.2.6.    Russia Achondroplasia Treatment Market

8.2.7.    Poland Achondroplasia Treatment Market

8.2.8.    BENELUX Achondroplasia Treatment Market

8.2.9.    NORDIC Achondroplasia Treatment Market

8.2.10.    Rest of Europe Achondroplasia Treatment Market

8.3.    Europe Achondroplasia Treatment Market, By Product Type

8.3.1.    RBM-007

8.3.2.    TA-46

8.3.3.    B-701

8.3.4.    Others

8.4.    Europe Achondroplasia Treatment Market, By End User

8.4.1.    Hospitals

8.4.2.    Clinics

8.4.3.    Others

8.5.    Europe Achondroplasia Treatment Market Attractiveness Index

8.5.1.    By Country

8.5.2.    By End User

8.5.3.    By Product Type

9.    Asia Pacific Achondroplasia Treatment Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    China Achondroplasia Treatment Market

9.2.2.    India Achondroplasia Treatment Market

9.2.3.    Japan Achondroplasia Treatment Market

9.2.4.    Australia and New Zealand Achondroplasia Treatment Market

9.2.5.    South Korea Achondroplasia Treatment Market

9.2.6.    ASEAN Achondroplasia Treatment Market

9.2.7.    Rest of Asia Pacific Achondroplasia Treatment Market

9.3.    Asia Pacific Achondroplasia Treatment Market, By Product Type

9.3.1.    RBM-007

9.3.2.    TA-46

9.3.3.    B-701

9.3.4.    Others

9.4.    Asia Pacific Achondroplasia Treatment Market, By End User

9.4.1.    Hospitals

9.4.2.    Clinics

9.4.3.    Others

9.5.    Asia Pacific Achondroplasia Treatment Market Attractiveness Index

9.5.1.    By Country

9.5.2.    By Product Type

10.    Middle East Achondroplasia Treatment Market, By Region

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    GCC Countries Achondroplasia Treatment Market

10.2.2.    Israel Achondroplasia Treatment Market

10.2.3.    Oman Achondroplasia Treatment Market

10.2.4.    Rest of Middle East Achondroplasia Treatment Market

10.3.    Middle East Achondroplasia Treatment Market, By Product Type

10.3.1.    RBM-007

10.3.2.    TA-46

10.3.3.    B-701

10.3.4.    Others

10.4.    Middle East Achondroplasia Treatment Market, By End User

10.4.1.    Hospitals

10.4.2.    Clinics

10.4.3.    Others

10.5.    Middle East Achondroplasia Treatment Market Attractiveness Index

10.5.1.    By Country

10.5.2.    By End User

10.5.3.    By Product Type

11.    Africa Achondroplasia Treatment Market, By Region

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    South Africa Achondroplasia Treatment Market

11.2.2.    Egypt Achondroplasia Treatment Market

11.2.3.    North Africa Achondroplasia Treatment Market

11.2.4.    Rest of Africa Achondroplasia Treatment Market

11.3.    Africa Achondroplasia Treatment Market, By Product Type

11.3.1.    RBM-007

11.3.2.    TA-46

11.3.3.    B-701

11.3.4.    Others

11.4.    Africa Achondroplasia Treatment Market, By End User

11.4.1.    Hospitals

11.4.2.    Clinics

11.4.3.    Others

11.5.    Africa Achondroplasia Treatment Market Attractiveness Index

11.5.1.    By Country

11.5.2.    By End User

11.5.3.    By Product Type

12.    Recommendation

12.1.    Market Strategy

13.    Competitive Landscape

13.1.    Competition Dashboard

13.2.    List and Company Overview of Global Key Players

13.3.    Company Profiles

13.3.1.    Ascendis Pharma A/S

13.3.1.1.    Company Overview

13.3.1.2.    Financial Overview

13.3.1.3.    Product Portfolio

13.3.1.4.    Key Developments

13.3.1.5.    Business Strategies

13.3.2.    BioMarin Pharmaceutical Inc.

13.3.3.    Ribomic Inc.

14.    Acronyms
 

Select License Type

Frequently Asked Questions

RBM-007, TA-46, B-701, and others are the drugs that are included in the drug type segment of market

The rising prevalence of achondroplastic dwarfism with no cure or prevention remedies, increasing government funding, rising development of drugs combined with the growing awareness segments are covered in market report

Market is segmented on the basis of product type, end user, and by region

Ascendis Pharma A/S, BioMarin Pharmaceutical Inc., Ribomic Inc., BridgeBio Pharma Inc., QED Therapeutics, BioMarin Pharmaceutical Inc., and Pfizer Inc. are the key participating players in the market



This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK